New report provides personalized wellness insights for the 18 million US adults currently living with post COVID symptoms

CAMBRIDGE, Mass. and OXFORD, England, Sept. 29, 2026 /PRNewswire/ — PrecisionLife, an AI-led precision medicine company focused on complex chronic diseases, has today launched the Post COVID DNA Wellness Report, translating more than five years of leading long COVID research into personalized genetic information that consumers can access directly.

The report enables individuals to explore their genetic profile, see how selected patterns in their DNA compare with those observed in research populations of people known to have long COVID, and be more informed about their health and general well-being. It is available directly from PrecisionLife in the US.

Post COVID conditions are a major public health burden. Latest figures indicate that 5.3% of U.S. adults – over 18 million people – are currently affected by long COVID^[1], with estimates suggesting that the condition may be linked to $170 billion in lost U.S. earnings each year and an annual global economic burden approaching $1 trillion^[2]. The scale and complexity of the condition, which causes diverse and debilitating symptoms, highlights the need for reliable, research-based information to be made more accessible.

The Post COVID DNA Wellness Report provides an at-home cheek swab kit for customers to collect a DNA sample. Following lab analysis, the personalized report presents results across the genetic patterns associated with six key biological mechanisms and identifies the genes contributing to each result, providing a detailed view of an individual’s genetic profile in the context of long COVID research.

The report draws on PrecisionLife’s world-leading research into both ME/CFS and long COVID, identifying the first reproducible disease mechanisms and associated patient subgroups for both conditions. This work uncovered over 180 genes linked to long COVID and the first clear genetic overlap with ME/CFS^[3],[4],[5]. The research was published in a series of open access, peer-reviewed papers in the Journal of Translational Medicine and presented at international ME/CFS and long COVID Conferences and is the most detailed genetic analysis of long COVID to date.

The Post COVID DNA Wellness Report was developed in collaboration with international patient advocacy groups, specialist clinicians and people with lived experience, representing over 100 million individuals living with long COVID and Post Acute Infection Syndromes (PAIS) globally. It is accompanied by a comprehensive educational guide summarizing published long COVID research, commonly reported symptoms and well-being approaches that have been discussed in the scientific literature.

“Long COVID has profoundly disrupted the lives of tens of millions of people, who often have little support. This report puts our peer-reviewed research directly into their hands, helping them understand their own individual genetic profile in the context of mechanisms known to impact on the condition from our research studies. We want them to be able to have more informed conversations that could improve their general well-being,” said Steve Gardner, Founder and CEO of PrecisionLife. “Launching this report also marks a critical milestone for PrecisionLife – it’s the first time our research has moved from the lab into an accessible consumer product, reflecting our broader mission to turn deep genetic research into real, actionable insights for the 5 billion patients affected by a wide range of complex chronic diseases globally.”

For more information, visit www.precisionlife.com/postcovid

Important information

The Post COVID DNA Wellness Report is intended for general wellness and educational purposes only. It provides research-based information about genetic patterns linked to biological mechanisms studied in post COVID research. Results are provided for biological context and are not a diagnosis, prediction, screening result or disease-risk assessment.

The report does not diagnose, detect, predict, prevent, monitor, treat or manage Long COVID or any other medical condition and is not intended for clinical use. It does not provide personalised medical, lifestyle, nutritional, supplement or treatment advice. If you have concerns about your health or symptoms, consult a qualified healthcare professional.

About PrecisionLife

PrecisionLife is an AI-enabled precision medicine company extending the benefits of precision medicine beyond oncology to chronic conditions affecting billions of people worldwide. Our proprietary genetic analysis platform enables us to uncover the biological drivers of complex diseases in major research studies. These insights power solutions that accelerate treatment development and drug repurposing studies for biopharma, help healthcare providers make better-informed decisions about diagnosis and care, and give consumers direct access to personalized, research-based information about their genetic profiles.

PrecisionLife.com

^[1] National Center for Health Statistics. U.S. Census Bureau, Household Pulse Survey, 2022–2024: Long COVID. Centers for Disease Control and Prevention. https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm. Accessed September 25, 2026.
^[2] Bansal A. (2025). https://doi.org/10.1038/s41533-025-00460-8.
^[3] Taylor, K., et al. (2023). https://doi.org/10.1186/s12967-023-04588-4.
^[4] Sardell, J., et al. (2025). https://doi.org/10.1186/s12967-025-06535-x.
^[5] Sardell, J., et al. (2026). https://doi.org/10.1186/s12967-026-08167-1.

View original content to download multimedia:https://www.prnewswire.com/news-releases/precisionlifes-post-covid-dna-wellness-report-places-world-leading-long-covid-genetic-research-directly-in-consumers-hands-302892004.html

SOURCE Precisionlife Ltd